Veracyte, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for VCYT, updated each market day.
VCYT AI Sentiment
AI sees no strong directional signal for Veracyte, Inc. stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Veracyte, Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Sector
Exchange
Market Cap
$3,261,451,956
Cap Tier
Employees
755
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Oct. 30, 2013
Website
VCYT Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VCYT Volatility
Veracyte, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
